Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma (N2013-02)

This study will combine three drugs: sorafenib, cyclophosphamide and topotecan. Adding sorafenib to cyclophosphamide and topotecan may increase the effectiveness of this combination. The investigators first need to find out the highest dose of sorafenib that can be given safely together with cyclophosphamide and topotecan. This is the first study to test giving these three drugs together and will help determine the highest dose of sorafenib that can safely be given together with cyclophosphamide and topotecan to patients with resistant/relapsed neuroblastoma.

NCT: NCT02298348

Locations: University of Chicago, Comer Children’s Hospital

Link: https://clinicaltrials.gov/ct2/show/NCT02298348?recrs=ad&cond=Neuroblastoma&locn=University+of+Chicago&cntry=US&age=0&draw=2&rank=4